Healthcare Industry News: BIND Therapeutics
News Release - September 3, 2014
BIND Therapeutics Appoints Two New Board MembersIndustry leaders, Eric K. Rowinsky, M.D. and Amy W. Schulman, join BIND’s Board of Directors
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company’s board of directors. Together the significant insights and expertise of these two industry leaders will help to guide BIND’s management team in the achievement of its business and development goals.
Eric K. Rowinsky, M.D., currently serves as Head of Research and Chief Medical Officer at Stemline Therapeutics and as a board member of Biogen Idec Inc. and was formerly Executive Vice President of Clinical Development and Regulatory at ImClone Systems. Amy W. Schulman is the Chief Executive Officer of Arsia Therapeutics and a Venture Partner at Polaris Partners. She is the former Executive Vice President and General Counsel of Pfizer Inc. and served as the Business Unit Lead for Pfizer’s Consumer Healthcare business, after serving as President of the Nutrition Business, which was sold to Nestle for $11.85 billion.
“We are excited to have Eric and Amy join Bind’s Board. Eric brings extensive clinical and regulatory expertise to BIND, particularly in oncology, at an important time as we continue to advance the development of BIND-014 and expand the therapeutic potential of our Accurin technology,” said Scott Minick, Chief Executive Officer at BIND. “Amy’s broad commercial experience and network within the pharmaceutical industry will be valuable as we further expand and evolve into a later-stage development company with a pipeline of exciting product opportunities, including both internal product candidates and through external partnerships.”
“Accurins represent an important step forward at the intersection of targeted therapies and nanomedicine,” said Eric Rowinsky. “By designing and optimizing Accurins with precisely controlled properties, BIND is well-positioned to develop a pipeline of highly selective therapies with improved efficacy and tolerability and I am excited to support the leadership team in pursuit of this goal.”
“I see significant potential in BIND’s proprietary Medicinal Nanoengineering platform to develop targeted therapeutics across a range of therapeutic indications,” said Amy Schulman. “I’m pleased to play a role in further establishing BIND as a leader in nanomedicine by developing important therapeutics designed to maximize patient benefit.”
Eric K. Rowinsky, M.D., has served as the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., since January 2012 and as a board member of Biogen Idec since 2010. Dr. Rowinsky is also an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc. from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky is also a member of the boards of directors of Coronado Biosciences, Inc. and Navidea Biopharmaceuticals, Inc. Dr. Rowinsky earned his medical degree from Vanderbilt University School of Medicine and a fellowship in medical oncology from the Johns Hopkins University.
Amy W. Schulman joined Arsia Therapeutics as Chief Executive Officer in August of 2014, at the same time she began her role as a Venture Partner at Polaris Partners. Ms. Schulman is also a Senior Lecturer at Harvard Business School, where she was appointed to the faculty in July of 2014. Prior to this, she joined Pfizer Inc. in 2008 and served as Executive Vice President and General Counsel and the Business Unit Lead for Pfizer’s Consumer Healthcare business until December 2013. Before joining Pfizer, she was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees. Ms. Schulman is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of Alnylam, The Brookings Institution and Wesleyan University.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer and metastatic castrate-resistant prostate cancer.
BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB and F. Hoffmann-La Roche Ltd. to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the Company's web site at www.bindtherapeutics.com.
Source: BIND Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.